Michael Har-Noy
Immunotherapy is now accepted as a new treatment modality for cancer. US FDA approved checkpoint blockage, anti-
CTLA4 and anti-PD1/L1, monoclonal antibody drugs and autologous CAR-T cells are the first generation of drugs with an
immunemediated anti-tumor mechanism. These immunotherapy drugs have demonstrated ability to control metastatic
disease and hematological malignancies. However, these first generation immunotherapy drugs work in only a limited
number of indications and in only a minority subset of patients within these limited indications, particularly the small
subset with tumors that express high mutational load status.
